West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance

WEST PHARMACEUTICAL SERVICES INC

2026-Q1 EPS reported $1.92 vs consensus $1.69 ▲ beat (+13.4%)

Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)
High-Value Components revenue $409.3M (+29.6%); HVP Delivery Devices $123.6M (+29.0%); West Vantage $150.6M (+11.6%)
Raised FY26 net sales guidance to $3.295-3.350B (prev $3.215-3.275B) and adj. EPS to $8.40-8.75 (prev $7.85-8.20)
Repurchased 1.2M shares for $297.6M at avg $243.57/share under February 2026 buyback program
Q2 2026 guidance introduced: net sales $830-850M, adj. EPS $2.05-2.12; SmartDose sale to AbbVie expected mid-year

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported the first quarter of 2026 results: revenue $844.9 million, EPS $1.92. Guidance raised.

Period: the first quarter of 2026
Revenue: $844.9 million
EPS: $1.92
Guidance: raised
Result: reported results

Exact text from the filing

West Reports First-Quarter 2026 Results – Strong Start to the Year and Raising Full Year Revenue and EPS guidance Exton, PA, April 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period) • Net sales of $844.9 million increased 21.0%; organic growth was 15.3%. • Diluted earnings per share ("EPS") of $1.92 increased 56.1%.

View on SEC.gov

1341 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-26-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.